The United Kingdom and the United States have hammered out a major bilateral deal that will keep zero tariffs on UK medicine shipments entering the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has pledged to raise expenditure on pharmaceuticals through the NHS. This pledge ensures that tariffs on these vital goods will stay at zero for a timeframe of the next three years.
This agreement is in response to recent statements to significantly raise duties on branded pharmaceutical imports, with increases discussed up to double the cost.
"This arrangement with the UK reinforces the international landscape for cutting-edge drugs and establishes much-needed fairness to U.S.–U.K. pharmaceutical trade," a statement said.
Trade Importance
Medicines are one of the UK's most significant goods shipped to the United States, which is by far the biggest destination for large British pharmaceutical firms.
Trade data indicate that in the 12 months to the end of the third quarter, the UK exported pharmaceutical products totaling £11.1bn to the US. This figure accounted for nearly one-fifth of all goods exports in that timeframe.
"This agreement secures jobs, stimulates capital expenditure and paves the way for the UK to become a global hub for biotech and pharma," a government official stated.
Key NHS Changes
The agreement involves several specific pledges from the British government:
- Revised Affordability Limit: The UK will increase the price threshold at which it judges new medicines to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a goal to double total NHS spending on medicines from 0.3 percent of GDP to 0.6% over the next decade.
- Payback Limit: The percentage manufacturers must pay back to the NHS to prevent overspending will be restricted at 15%. Last year, refunds were more than twenty percent.
Recent Tensions
This agreement takes place against a protracted dispute between the pharmaceutical industry and the British authorities over drug pricing and NHS adoption.
This friction were heightened by claims that American patients were charged several times more for the same drugs than patients in the other developed nations.
Over the last 18 months, several major manufacturing plans in the UK have been paused or abandoned, while major funding commitments have been announced toward projects in the United States.
The Science Minister stated that the NHS must spend more on medicines, noting that its budget allocation on drugs had declined as a share of its overall budget over the previous ten-year period.
